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The role of EGFR mutation as a prognostic
factor in survival after diagnosis of brain
metastasis in non-small cell lung cancer: a
systematic review and meta-analysis
Wen-Ya Li1, Ting-Ting Zhao2, Hui-Mian Xu3, Zhen-Ning Wang3, Ying-Ying Xu2, Yunan Han2,4, Yong-Xi Song3,
Jian-Hua Wu3, Hao Xu5, Song-Cheng Yin3, Xing-Yu Liu3 and Zhi-Feng Miao3*
Abstract
Background: The brain is a common site for metastasis in non-small-cell lung cancer (NSCLC). This study was
designed to evaluate the relationship between the mutational of the epidermal growth factor receptor (EGFR) and
overall survival (OS) in NSCLC patients with brain metastases.
Methods: Searches were performed in PubMed, EmBase, and the Cochrane Library to identify studies evaluating
the association of EGFR mutation with OS in NSCLC patients through September 2017.
Results: 4373 NSCLC patients with brain metastases in 18 studies were involved. Mutated EGFR associated with
significantly improved OS compared with wild type. Subgroup analyses suggested that this relationship persisted in
studies conducted in Eastern, with retrospective design, with sample size ≥500, mean age of patients ≥65.0 years,
percentage male < 50.0%, percentage of patients receiving tyrosine kinase inhibitor ≥30.0%. Finally, although
significant publication bias was observed using the Egger test, the results were not changed after adjustment using
the trim and fill method.
Conclusions: This meta-analysis suggests that EGFR mutation is an important predictive factor linked to improved
OS for NSCLC patients with brain metastases. It can serve as a useful index in the prognostic assessment of NSCLC
patients with brain metastases.
Keywords: Lung cancer, EGFR, Brain metastasis, Prognosis, Meta analysis
Background
Lung cancer remains the leading cause of cancer-related
deaths worldwide, and nearly 85% of lung patients are
diagnosed with non-small-cell lung cancer (NSCLC) [1].
Despite continued efforts, innovations, and progress in
diagnosis and treatment, the 5-year overall survival (OS)
for patients with advanced NSCLC is only 15% [2]. Over
25% of NSCLC patients present with brain metastases at
diagnosis, and nearly 45% of autopsies of NSCLC patients
show brain metastasis [3–5]. The median OS of lung
cancer patients with brain metastases with no treatment
ranges from 4 to 11 weeks [5], while this can be prolonged
to 14months if they receive local treatments such as
neurosurgery, stereotactic radiosurgery, or brain radiation
therapy [6]. To best improve the OS and quality of life for
patients receiving local treatments, selection of the opti-
mal treatment option should be based on definite prog-
nostic factors of each specific patient.
Genetic alterations of the epidermal growth factor re-
ceptor (EGFR) occur in approximately 20% of patients
with lung adenocarcinomas in Western countries and
40–60% in East Asia for [7–11]. Currently, tyrosine kin-
ase inhibitors (TKIs) are widely used in NSCLC accord-
ing to the EGFR mutation type. TKIs can reduce the
incidence of long-term treatment failure in patients with
or without brain metastases, possibly through EGFR
* Correspondence: zfmiao@cmu.edu.cn
3Department of Surgical Oncology, First Hospital of China Medical University,
Shenyang 110001, Liaoning Province, China
Full list of author information is available at the end of the article
© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Li et al. BMC Cancer          (2019) 19:145 
https://doi.org/10.1186/s12885-019-5331-z
signaling pathways promoting factors associated with
oncogenic and metastatic progression such as angiogen-
esis, cellular proliferation, and epithelial mesenchymal
transition [12, 13]. Although these relationships have
been demonstrated, the association of EGFR mutation
with OS in NSCLC patients with brain metastases re-
mains controversial.
Several studies have illustrated that EGFR mutations
are significantly associated with longer OS in NSCLC
patients with brain metastases [14–19], yet numerous
other studies show no association between EGFR muta-
tions and OS for these patients [20–29]. Two studies
have even suggested that EGFR mutations may decrease
OS [30, 31]. Clarifying the relationship between EGFR
and OS in NSCLC patients with brain metastases is par-
ticularly important, as it has not been definitively deter-
mined. Therefore, we conducted a meta-analysis of
available studies to determine if a correlation exists be-
tween EGFR status and OS in NSCLC patients with
brain metastases. The relationship was further quanti-
tively probed in subpopulations of patients with specific
characteristics using stratified analyses.
Methods
Data sources, search strategy, and selection criteria
This study was conducted and reported according to the
meta-analysis of observational studies in epidemiology
protocol [32]. Any observational study published in Eng-
lish and examining the relationship between EGFR sta-
tus and OS in NSCLC patients with brain metastases
was eligible for inclusion in our study, and no restrictions
was placed on publication status (published, or in press).
Briefly, we searched PubMed, EmBase, and Cochrane li-
brary for studies published up to September 2017 using
the following search terms: (“brain metastases” OR “cere-
bral metastases” OR “neoplasm metastasis” OR “central
nervous system” OR “encephalon”) AND (“epidermal
growth factor receptor” OR “receptor, epidermal growth
factor” OR “EGFR” OR “EGFR mutation”) AND (“lung”
OR “pulmonary”) AND (“neoplasms” OR “cancer” OR
“carcinoma” OR “neoplasm”) AND “human” AND “Eng-
lish”. We also conducted manual searches of reference
lists from all relevant original and review articles to iden-
tify additional eligible studies. Study title, study design,
disease status, exposure, control, and outcome variables
were used to identify relevant studies. All analyses were
based on previously published studies; thus, no ethical ap-
proval or patient consent were required.
The literature search and study selection were inde-
pendently undertaken by 2 authors using a standardized
approach, and any inconsistencies were settled by the
primary author until a consensus was reached. Studies
were included in this meta-analysis if they met the fol-
lowing criteria: (1) Study design: study with prospective
or retrospective observational design; (2) Participants:
adult NSCLC patients (≥18 years old) with brain metas-
tases; (3) Exposure: EGFR mutations and wide-type; and
(4) Outcomes: OS. Studies were excluded for the follow-
ing reasons: (1) Participants with other disease; (2) pa-
tients with other histologies NSCLC; (3) No available
data for statistics; or (4) Publication type was a review,
comment, or letter to the editor.
Data collection and quality assessment
The following data from each study were extracted inde-
pendently by two authors: first author’s name, publication
year, country, study design, disease stage, percentage of
adenocarcinoma, sample size, mean age, percentage male,
percentage smokers, percentage TKI, and OS. Any dis-
agreements were resolved by a consensus. We also utilized
a 9-star system using the Newcastle-Ottawa Scale (NOS)
for assessing the quality of the observational studies based
on selection (4 items), comparability (1 item), and out-
come (3 items) [33]. We regarded a study with a score ≥ 7
as being of high quality.
Statistical analysis
We examined the relationship between EGFR status and
OS for NSCLC patients with brain metastases based
upon hazard ratios (HRs) and 95% confidence intervals
(CIs) published in each study. The random-effects model
was employed to calculate summary HRs and 95% CIs for
EGFR mutations versus EGFR wild-type for OS [34, 35].
Potential heterogeneity across the studies was examined
using the Cochran’s Q-statistic and I2 statistic [36, 37]. A
sensitivity analysis was conducted by removing each indi-
vidual study from the meta-analysis [38]. Meta-regression
was performed to explore the source of heterogeneity
based on percentage of adenocarcinoma, sample size,
mean age, percentage male, percentage smokers, and per-
centage TKI [39]. Subgroup analyses were conducted
based on country (Eastern versus Western), study design
(prospective versus retrospective), disease status (adeno-
carcinoma versus both), sample size (≥500 versus < 500),
mean age (≥65.0 versus < 65.0 years), percentage male
(≥50.0% versus < 50.0%), percentage smokers (≥50.0% ver-
sus < 50.0%), percentage of patients receiving TKIs
(≥30.0% versus < 30.0%), and study quality (high versus
low). The ratio between subgroups was calculated via the
Chi-square test and meta-regression [39]. Publication bias
was qualitatively evaluated using a funnel plot and quanti-
tatively assessed using the Egger and Begg tests [40, 41].
All reported P values are 2-sided and P values < 0.05 are
regarded as statistically significant for all included studies.
Statistical analyses were conducting using STATA
software (version 10.0; Stata Corporation, College
Station, TX, USA).
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Results
Literature search
A total of 591 citations from PubMed, 681 citations from
EmBase, and 119 citations from the Cochrane Library were
identified, for a total of 1391 records. Of these, 1306 were
excluded as duplicates or irrelevant studies. Eighty-five
studies were selected for full-text assessment, of which 67
studies were excluded: 29 studies lacked sufficient data, 11
studies lacked appripriate controls, 23 studies reported pa-
tients with other disease, and 4 studies were reviews, com-
ments, or letters to the editor. Finally, 18 studies were
pooled into the meta-analysis [14–31]. The study selection
process is presented in Fig. 1.
Characteristics of selected studies
Of the 18 included studies (encompassing a total of
4373 NSCLC patients with brain metastases), 3 had a
prospective design [18, 26, 30] and 15 had a retrospect-
ive design [14–17, 19–25, 27–29, 31]. Nine included
studies were from Asia [14, 15, 17, 18, 20, 24–26, 31],
and 9 were from Europe or America [16, 19, 21–23, 27–30].
All studies were published between 2009 and 2017,
and 41–1127 patients were included in each study.
Five studies included only patients with lung adeno-
carcinoma [14, 18, 20, 22, 26], while the other studies
included various types of lung cancers [15–17, 19, 21,
23–25, 27–31]. The mean age of included patients
ranged from 55.0–67.0 years, percentage male ranged
from 28.3 to 66.2%, percentage smokers ranged from
21.9 to 77.4%, and percentage of patients receiving
TKI ranged from 5.1 to 44.0%. Study quality was
assessed using the NOS, and 4 studies scored 8 [19,
20, 22, 23], 5 studies scored 7 [14–16, 25, 26], 5 stud-
ies scored 6 [21, 27, 28, 30, 31], and the remaining 4
studies scored 5 [17, 18, 24, 29]. The general charac-
teristics of the included studies are presented in
Table 1.
Meta-analysis
After pooling all included studies, a statistically sig-
nificant improvement in OS was found for NSCLC
patients with brain metastases with EGFR mutations
compared with wild-type EGFR (HR: 0.73; 95% CI:
0.54–0.99; P = 0.045; Fig. 2). Substantial heterogeneity
was detected across the included studies (I2 = 84.6%;
P < 0.001), so we conducted a sensitivity analysis
(Fig. 3 and Table 2). The results of the sensitivity
analysis were consistent after excluding several studies
[21, 22, 25–27, 31], with the magnitude of heterogen-
eity not significantly decreasing. However, when we
excluded the study conducted by Arrieta et al. [30],
the heterogeneity among the included studies de-
creased to 66.9% and EGFR mutations showed large
improvement for OS (HR: 0.69; 95% CI: 0.54–0.89; P
= 0.005). This study specifically included a lower per-
centage of adenocarcinoma, which may have contrib-
uted to lower incidence of EGFR mutations.
Meta-regression and subgroup analyses
The heterogeneity test showed a P < 0.05, indicating
that heterogeneity was statistically significant in the
overall analysis. Therefore, a meta-regression analysis
was conducted based on percentage of adenocarcin-
oma, sample size, mean age, percentage male, per-
centage smokers, and percentage receiving TKI to
evaluate potential sources of heterogeneity. The re-
sults of the analysis are presented in Additional file 1.
Overall, we noted that the percentage of patients receiv-
ing TKI might affect the relationship between EGFR status
and OS in NSCLC patients with brain metastases (P =
0.015), while percentage of adenocarcinoma (P = 0.279),
sample size (P = 0.671), mean age (P = 0.112), percentage
male (P = 0.275), and percentage smokers (P = 0.196) were
all not significant factors contributing to this relationship.
The results of the subgroup analysis are listed in
Table 3. Overall, we noted that EGFR mutations were
associated with significantly improved OS in studies
conducted in Eastern Countries (HR: 0.59; 95% CI:
0.37–0.92; P = 0.021) and in those with retrospective de-
sign (HR: 0.70; 95% CI: 0.55–0.89; P = 0.004), sample size
≥500 (HR: 0.52; 95% CI: 0.36–0.76; P = 0.001), mean age
of included patients ≥65.0 years (HR: 0.59; 95% CI: 0.36–
0.98; P = 0.043), percentage male < 50.0% (HR: 0.60; 95%
CI: 0.43–0.82; P = 0.002), percentage receiving TKI ≥
30.0% (HR: 0.60; 95% CI: 0.48–0.75; P < 0.001), and in
studies with high quality (HR: 0.67; 95% CI: 0.50–0.90;
Fig. 1 Flow diagram of the study selection process
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Table 1 Baseline characteristic of studies included in the systematic review and meta-analysis
Author Publication
year
Country Study design Disease
stage
Percentage of
adenocarcinoma (%)
Sample
size
Mean age
(years)
Percentage
male (%)
Percentage
of smoker (%)
Percentage
of TKI (%)
NOS
score
Hsiao
[14]
2013 China Retrospective I–IV 100.0 139 NA 41.0 30.0 32.0 7
Han [20] 2016 China Retrospective I–IV 100.0 234 NA 53.4 44.0 30.3 8
Russo
[21]
2017 Italy Retrospective IIIb-IV 73.0 137 66.2 59.1 77.4 NA 6
Baek [15] 2016 Korea Retrospective IV 70.0 259 68.0 64.5 59.1 NA 7
Stanic
[22]
2014 Slovenia Retrospective I–IV 100.0 629 64.0 51.8 72.0 NA 8
Hsu [16] 2016 Canada Retrospective IV NA 543 66.0 40.0 NA 41.0 7
Hendriks
[23]
2014 The
Netherlands
Retrospective NA 91.9 124 61.9 41.9 72.6 37.1 8
Iuchi [17] 2014 Japan Retrospective Ia-IV 79.4 1127 67.0 65.2 64.2 42.3 5
Arrieta
[30]
2009 Mexico Prospective IIIb-IV 64.8 293 60.7 56.0 53.9 12.6 6
Lee [24] 2012 China Retrospective I-III 93.0 43 59.0 53.0 37.0 44.0 5
Iuchi [18] 2013 Japan Prospective NA 100.0 41 NA 29.3 21.9 NA 5
Li [25] 2015 China Retrospective NA 83.8 136 NA 52.9 58.8 30.9 7
Luo [31] 2013 China Retrospective I-IV 82.4 136 55.0 61.0 37.5 5.1 6
Zhuang
[26]
2013 China Prospective I-IV 100.0 54 61.7 42.6 NA 42.6 7
Tomasini
[27]
2016 France Retrospective IV 89.4 142 62.0 66.2 76.1 NA 6
Eichler
[19]
2010 US Retrospective I-IV 94.0 93 60.9 33.0 57.0 19.0 8
Mak [28] 2015 US Retrospective NA NA 172 60.0 45.0 70.0 42.0 6
Wang
[29]
2015 US Retrospective I-III 85.9 71 61.9 50.7 NA 21.1 5
Fig. 2 Forest plot of the relationship between EGFR mutation and OS in NSCLC patients with brain metastases. Each study is shown by the point
estimate of the HR and 95% CI (extending lines)
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P = 0.007). No other significant differences were detected
based on other pre-defined factors. Furthermore, there
was no evidence of a factor-specific difference in the HR
for OS among patients with EGFR mutations compared
to patients with wild-type EGFR (Table 3).
Publication Bias
Potential publication bias was detected via funnel plot
(Fig. 4). Although the Begg test [41] showed no evidence
of publication bias (P = 0.889), the Egger test [40]
showed potential evidence of publication bias (P =
Fig. 3 Results of the sensitivity analysis. Results when each study is excluded are shown by the point estimate of the HR and 95% CI
(extending lines)
Table 2 Sensitivity analysis
Excluding study HR and 95% CI P value Heterogeneity (%) P value for heterogeneity
Hsiao [14] 0.75 (0.55–1.03) 0.073 84.3 < 0.001
Han [20] 0.75 (0.55–1.02) 0.069 85.1 < 0.001
Russo [21] 0.70 (0.51–0.96) 0.027 85.2 < 0.001
Baek [15] 0.76 (0.56–1.04) 0.087 84.2 < 0.001
Stanic (a) [22] 0.74 (0.54–1.02) 0.064 85.0 < 0.001
Stanic (b) [22] 0.70 (0.51–0.97) 0.033 85.2 < 0.001
Hsu [16] 0.74 (0.53–1.02) 0.065 84.7 < 0.001
Hendriks [23] 0.73 (0.53–1.00) 0.052 85.4 < 0.001
Iuchi [17] 0.76 (0.56–1.03) 0.076 81.8 < 0.001
Arrieta [30] 0.69 (0.54–0.89) 0.005 66.9 < 0.001
Lee [24] 0.75 (0.55–1.02) 0.070 85.0 < 0.001
Iuchi [18] 0.77 (0.57–1.04) 0.089 84.3 < 0.001
Li [25] 0.72 (0.52–1.00) 0.049 85.4 < 0.001
Luo [31] 0.69 (0.50–0.96) 0.026 84.9 < 0.001
Zhuang [26] 0.71 (0.52–0.96) 0.029 85.3 < 0.001
Tomasini [27] 0.73 (0.53–0.99) 0.046 85.4 < 0.001
Eichler [19] 0.75 (0.55–1.03) 0.073 84.4 < 0.001
Mak [28] 0.73 (0.53–1.01) 0.056 85.3 < 0.001
Wang [29] 0.73 (0.53–1.01) 0.056 85.3 < 0.001
Li et al. BMC Cancer          (2019) 19:145 Page 5 of 9
0.008). The results were not changed following adjust-
ment with the trim and fill method (HR: 0.73; 95% CI:
0.54–0.99; P = 0.045) [42].
Discussion
Our meta-analysis analyzed 3 prospective studies and 15
retrospective studies to explore possible correlations be-
tween EGFR status and OS for NSCLC patients with
brain metastases. The included 18 studies involved 4373
NSCLC patients with brain metastases. Our results sup-
port that mutated EGFR associates with significant im-
provement in OS compared with wild-type EGFR.
Stratified analyses determined that a similar effect was
seen in studies conducted in Eastern Countries and
studies with retrospective design, sample size ≥500,
mean age of included patients ≥65.0 years, percentage
male < 50.0%, percentage receiving TKI ≥ 30.0%, and
studies with high quality.
The results were predominantly consistent with those
of previous studies, which have demonstrated that EGFR
mutations could prolong OS over wild-type EGFR. Hsiao
et al. [14] suggested that EGFR mutation is an independ-
ent predictive factor for treatment response and OS in
lung adenocarcinoma patients with brain metastases.
They point out that radiation could induce nuclear
translocation of wild-type, augmenting repair of DNA
double-strand breaks in lung adenocarcinoma cells [43].
Alternatively, irradiation could delay DNA repair and
decrease clonogenic survival in NSCLC cells with mu-
tated EGFR [44, 45]. Baek et al. indicated that EGFR
Table 3 Subgroup analyses
Group Number of
cohorts
HR and 95% CI P value Heterogeneity
(%)
P value for
heterogeneity
Ratio between
subgroups
P value between-
subgroup
Country
Eastern
Countries
9 0.59 (0.37–0.92) 0.021 76.3 < 0.001 0.68 (0.38–1.21) 0.189
Western
Countries
10 0.87 (0.61–1.25) 0.455 81.6 < 0.001
Study design
Prospective 3 0.81 (0.18–3.75) 0.792 83.7 0.002 1.16 (0.25–5.38) 0.852
Retrospective 16 0.70 (0.55–0.89) 0.004 64.7 < 0.001
Disease status
Adenocarcinoma
6 0.65 (0.36–1.18) 0.154 75.5 0.001 0.86 (0.43–1.72) 0.660
Both 13 0.76 (0.53–1.10) 0.152 86.7 < 0.001
Sample size
500 or more 2 0.52 (0.36–0.76) 0.001 49.4 0.160 0.68 (0.41–1.10) 0.117
< 500 17 0.77 (0.56–1.06) 0.106 81.4 < 0.001
Mean age (years)
65.0 or older 4 0.59 (0.36–0.98) 0.043 73.2 0.011 0.65 (0.35–1.19) 0.160
< 65.0 11 0.91 (0.65–1.28) 0.595 78.0 < 0.001
Percentage male (%)
50.0 or greater 12 0.81 (0.55–1.19) 0.290 86.2 < 0.001 1.35 (0.82–2.23) 0.242
< 50.0 7 0.60 (0.43–0.82) 0.002 42.9 0.105
Percentage of current/past smokers (%)
50.0 or greater 11 0.78 (0.52–1.17) 0.239 87.5 < 0.001 1.50 (0.64–3.50) 0.349
< 50.0 5 0.52 (0.25–1.11) 0.092 81.1 < 0.001
Percentage of patients using TKI (%)
30.0 or greater 9 0.60 (0.48–0.75) <
0.001
26.2 0.211 0.59 (0.32–1.10) 0.099
< 30.0 4 1.01 (0.57–1.81) 0.963 87.3 < 0.001
Study quality
High 10 0.67 (0.50–0.90) 0.007 58.0 0.011 0.85 (0.47–1.53) 0.585
Low 9 0.79 (0.47–1.31) 0.357 88.3 < 0.001
CI confidence intervals, HR hazards ratios, TKI tyrosine kinase inhibitor, bold entries P<0.05
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mutation could increase incidence of brain metastases
and improve OS in NSCLC patients with brain metasta-
ses. This significant improvement in OS was mainly ob-
served if the brain is the first metastatic site [15]. Several
other studies have demonstrated EGFR mutations to as-
sociate with an increased risk of brain metastases and
prolonged survival after brain metastases in NSCLC pa-
tients [16–19]. A possible reason could be that
EGFR-TKI could prevent brain metastases progression
in NSCLC patients with activating EGFR mutations
compared with those treated with conventional chemo-
therapy [46]. Further, different mechanisms and drug
sensitivities between synchronous and metachronous
brain metastases exist since metachronous brain metas-
tases always accompany central nervous system symp-
toms while synchronous brain metastases are often
asymptomatic.
Several studies included in our analysis reported in-
consistent results. Numerous studies found that EGFR
mutations could not predict survival or local control in
NSCLC patients with brain metastases [20–29]. This
lack of significant difference could be due to the studies
being designed to evaluate the incidence of brain metas-
tases or the treatment effects as primary endpoint. The
sample size of these studies was smaller than expected,
and broad 95% CIs were found, leading to no statistically
significant differences being found. In addition, Arrieta
et al. suggested that EGFR expression significantly asso-
ciated with worse OS, possibly due to the low frequency
of EGFR expression [30]. Luo et al. suggested that me-
dian OS was 24.5 and 15.0 months in EGFR wild-type
and mutant groups, respectively [31]. The major reason
for this could be that the use of EGFR-TKI therapy after
diagnosis of brain metastases was associated with longer
survival [47, 48].
Subgroup analyses suggested that EGFR mutations
were associated with improved OS in several subsets.
The combined higher incidence of EGFR mutation
and sufficient statistical power indicated a relationship
between EGFR status and OS in NSCLC patients with
brain metastases. Further, high percentages of patients
using EGFR-TKI produced better effect on OS. This
relationship was not observed in numerous subsets,
and these conclusions may be unreliable since smaller
cohorts were included. Therefore, we presented our
relative results and provided a synthetic and compre-
hensive review.
Although this is not the first meta-analysis to evaluate
the relationship between EGFR status and OS in NSCLC
patients with brain metastases, this study has several
strengths over the previous meta-analysis [49]. The main
purpose of previous meta-analysis was to investigate the
risk of brain metastases in EGFR mutations or wild type,
and secondary outcome was OS in NSCLC patients with
brain metastases. They point out EGFR mutation pa-
tients was associated with an increased risk of brain me-
tastases than those with wild type. Further, EGFR
mutation prolonged OS in patients with brain metasta-
ses compared with wild-type EGFR. However, the result
for NSCLC patients with brain metastases just based on
7 studies, and numerous studies were neglected. Fur-
thermore, no stratified analyses were conducted based
on confounding factors. The current quantitative
meta-analysis included 18 studies involved 4373 NSCLC
patients with brain metastases comprised a wide range
of characteristics of patients and the results of stratified
analyses according to country, study design, disease sta-
tus, sample size, mean age, percentage male, percentage
smokers, percentage of patients receiving TKIs, and
study quality were calculated.
Fig. 4 Publication bias
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The limitations of this study are as follows: (1) recur-
sive partitioning analysis, Karnofsky Performance scale,
activity of systemic disease, type of treatment, and dis-
ease status may be associated with OS in NSCLC with
brain metastases, while these data were not available in
mostly included studies or unable to conduct stratified
analysis; (2) several other molecular alterations in central
nervous system response to TKI therapy were not re-
ported in mostly studies; (3) most included studies had a
retrospective design, so recall and selection biases might
affect the relationship found between EGFR status and OS;
(4) publication bias is an inevitable problem since this study
is based on published articles, and ongoing or unpublished
studies were not included in this meta-analysis; and (5) in-
herent limitations are found in any meta-analysis using
pooled data when individual data are not available.
Conclusions
The pooled results show that EGFR mutation is associ-
ated with a significant improvement in OS when com-
pared with wild-type EGFR. Further, this relationship
manifested in studies conducted in Eastern Countries
and studies with retrospective design, sample size ≥500,
mean age of included patients ≥65.0 years, percentage
male < 50.0%, percentage receiving TKI ≥ 30.0%, and
high quality. Further large-scale prospective studies
should be conducted to verify this relationship and ex-
plore this relationship in specific patient subsets, espe-
cially for broader implications of improved OS in
patients with EGFR mutant brain metastases.
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